ImmunoTEP 68Ga-IMP-288
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ImmunoTEP 68Ga-IMP-288, covering 2018-07-27 to 2018-07-27. Get the full timeline:
Most recent: Clinical Trial Update: ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA [Phase 1, Phase 2]